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Abstract
Background: Cisplatin (cis-diamminedichloroplatinum (II), CDDP) and its analogues constitute an important class of
anticancer drugs in the treatment of various malignancies; however, its effectiveness is frequently affected by
mutations in genes involved in the repair and signaling of cisplatin-induced DNA damage. These observations
necessitate a need for a better understanding of the molecular events governing cellular sensitivity to cisplatin.
Results: Here, we show that hMSH5 mediates sensitization to cisplatin-induced DNA damage in human cells. Our
study indicates that hMSH5 undergoes cisplatin-elicited protein induction and tyrosine phosphorylation. Silencing
of hMSH5 by RNAi or expression of hMSH5 phosphorylation-resistant mutant hMSH5
Y742F elevates cisplatin-induced
G2 arrest and renders cells susceptible to cisplatin toxicity at clinically relevant doses. In addition, our data show
that cisplatin promotes hMSH5 chromatin association and hMSH5 deficiency increases cisplatin-triggered g-H2AX
foci. Consistent with a possible role for hMSH5 in recombinational repair of cisplatin-triggered double-strand breaks
(DSBs), the formation of cisplatin-induced hMSH5 nuclear foci is hRad51-dependent.
Conclusion: Collectively, our current study has suggested a role for hMSH5 in the processing of cisplatin-induced
DSBs, and silencing of hMSH5 may provide a new means to improve the therapeutic efficacy of cisplatin.
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Background
Despite being members of the MMR protein family, the
MSH5 homologues have not been demonstrated to
function in MMR. Instead, studies in mice, C. elegans,
and S. cerevisiae have shown that MSH5 plays an array
of diverse functions ranging from meiotic recombina-
tional DSB repair, maintenance of chromosome integ-
rity, to DNA damage response [1-6]. Purified hMSH4-
hMSH5 protein complexes have been shown to possess
binding activities towards recombination intermediate
structures including the Holliday junction [7], and endo-
genous hMSH5 has been shown to interact with a Holli-
day junction binding protein [8]. In addition, hMSH5
forms chromosomal foci in human fetal oocytes at dif-
ferent stages of meiotic prophase I [9].
Coherent with a conjectured role in recombinational
DSB repair, hMSH5 has been reported to interact with
several proteins related to DSB sensing and repair,
including the c-Abl tyrosine kinase and HR protein
hRad51 [10,11]. It is observed that RAD51 silencing in
MSH5-deficient C. elegans oocytes can result in chro-
mosome fragmentation [6], suggesting that MSH5 and
RAD51 may play a synergistic role in DSB processing at
least during meiosis in C. elegans. In addition, interac-
tion between endogenous hMSH5 and hMRE11 has
been observed in human alveolar basal epithelial derived
lung adenocarcinoma A549 cells [8]. Studies performed
with mouse models and human patient samples have
also suggested a role for hMSH5 in class switch recom-
bination during B and T cell development, whereas
hMSH5 deficiency associates with long microhomologies
at Ig switch joints [12]. These observations have raised
the possibility that, through interacting with various
DSB repair proteins, hMSH5 could exert multiple roles
in DNA damage surveillance and DSB repair. Although
the link between hMSH5 mutation and diseases in
humans has not been explored, a genome-wide associa-
tion study has designated the hMSH5 locus at 6p21.33
as a high risk factor for lung cancer development [13].
In addition to its potential role in DNA repair, hMSH5
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cells treated with ionizing radiation–a process involved
with the activation of p73 and caspase-3 [14].
In the present study, we have investigated the role of
hMSH5 in cisplatin-induced DNA damage response. Cis-
platin is the drug of choice for combination chemother-
apy of testicular cancers [15], and hMSH5 is known to be
expressed abundantly in the testis [16]. The cytotoxicity
of cisplatin is mainly caused by its ability to form adducts
with DNA. The major types of biologically active cispla-
tin adducts are 1,2-intrastrand crosslinks between gua-
nines or between guanine and adenine, and, to a lesser
extent, interstrand DNA crosslinks [17]. These DNA dis-
tortions can effectively block the progression of DNA
replication and activate cell cycle checkpoint [18-20].
Cisplatin-induced DNA intrastrand crosslinks can be
effectively removed by nucleotide excision repair (NER)
[17,21]; however, the removal of cisplatin-induced inter-
strand crosslinks requires the HR pathway [22]. The
importance of recombinational repair in resolving cispla-
tin-induced DNA damage has also been suggested by the
observation that cisplatin increases the rate of recombi-
nation, presumably attributing to the formation of DSB
[23,24]. In addition, the single-strand breaks generated
from the processing of cisplatin-induced DNA lesions by
NER can also be converted into one-ended DSBs when
single-strand breaks collide with the replication forks
[25]. Nevertheless, it becomes increasingly clear that HR
plays an essential role in the repair of cisplatin-induced
DSBs that may arise from stalled replication forks. In
addition, HR-deficient cells are highly sensitive to DNA
damaging agents that induce DNA cross-links, due to
replication blockade.
Results
Cisplatin leads to hMSH5 induction
Analysis of the effects of cisplatin on the levels of
h M S H 5e x p r e s s i o ni nt h r e ec e l ll i n e s –293, 293T, and
A549–showed that cisplatin promoted hMSH5 induc-
tion in a time- and dose-dependent manner (Figure 1A
and 1B). Significant hMSH5 induction could be
observed 4 hrs post-treatment by as low as 2 μM cispla-
tin; in comparison to 293 and 293T cells, hMSH5
induction in A549 cells appeared to be more robust in
response to higher dose of cisplatin (Figure 1A and 1B).
Since over-expressed hMSH5 can be localized in both
cytoplasm and nucleus [26,27], we next examined cispla-
tin-triggered hMSH5 cytoplasmic and nuclear redistri-
bution in 293T and A549 cells. Immunoblotting analysis
demonstrated that the endogenous hMSH5 protein was
expressed in both cytoplasm and nucleus, of which the
nuclear fraction displayed a moderate level of hMSH5
induction in response to cisplatin treatment in 293T
and A549 cells (Figure 1C).
It is well known that HR is required for the resolution
of cisplatin-induced DSBs [22-24], and most of the cis-
platin-induced DSBs are created at replication forks dur-
ing S phase [28]. Interestingly, in synchronized cells,
hMSH5 was predominantly expressed in the S and G2
phases of the cell cycle, of which cells in the S phase
showed the most abundant hMSH5 expression (Figure
2A). Evidently, following cisplatin treatment, a signifi-
cant hMSH5 induction was observed in S phase cells
(Figure 2B). The results of cytoplasmic/nuclear fractio-
nation experiments were consistent with the view that
most of the induction occurs in the nucleus of S phase
cells (Figure 2C). Together, these observations raise a
possibility that hMSH5 may be involved in the proces-
sing of cisplatin-induced DSBs.
c-Abl phosphorylates hMSH5 at Tyr
742 in response to
cisplatin-induced DNA lesions
We have previously shown that the interaction between
hMSH5 and the c-Abl kinase could lead to hMSH5 tyr-
osine phosphorylation and c-Abl activation in response
to ionizing radiation (IR) [10,14]. To determine whether
the hMSH5 and c-Abl interaction is also relevant to cis-
platin-triggered DNA damage response, we analyzed c-
Abl-mediated hMSH5 tyrosine phosphorylation in
293T/f-hMSH5 cells treated with cisplatin. Western blot
analysis indicated that hMSH5 tyrosine phosphorylation
became detectable at 2 hrs, peaked at 6 hrs, and began
to fade away at 24 hrs post treatment (Figure 3A). This
pattern of hMSH5 tyrosine phosphorylation appeared to
be temporally correlated with cisplatin-induced hMSH5
nuclear foci formation (Figure 3B and Additional file 1:
Figure S1). Approximately 9% of cells possessing
hMSH5 nuclear foci were observed 1 hr after cisplatin
treatment, and it was further increased to 19.2% at 6 hrs
before declining to 13.7% at 24 hrs (Figure 3B). These
results implicated a potential role for hMSH5 tyrosine
phosphorylation in the processing of cisplatin-induced
DNA lesions.
To validate that Tyr
742 could also be targeted by c-Abl
in human cells, immunoaffinity-purified hMSH5 pro-
teins from cisplatin-treated and untreated 293T/f-
hMSH5 and 293T/f-hMSH5
Y742F cells were analyzed for
tyrosine phosphorylation. As shown in Figure 4B, cispla-
tin elicited readily detectable hMSH5 tyrosine phosphor-
ylation, and this phosphorylation was largely absent in
cells either expressing hMSH5
Y742F or treated with c-
Abl kinase inhibitor imatinib. It is known that hMSH5
tyrosine phosphorylation dissociates the binding of
hMSH5 to c-Abl [10]. Consistent with this is the obser-
vation that hMSH5
Y742F could not dissociate from c-Abl
following cisplatin treatment (Figure 4B). In addition,
hMSH5 Tyr
742 phosphorylation could also be triggered
by IR (data not shown), suggesting that c-Abl-mediated
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742 is not unique to cis-
platin-induced DNA lesions.
Cisplatin stimulates hMSH5 chromatin association
To analyze cisplatin-triggered hMSH5 chromatin associa-
tion, ChIP analysis was performed with an a-acetyl histone
H3 antibody using 293T/f-hMSH5 and 293T/f-
hMSH5
Y742F cells. Western blot was employed to deter-
mine the levels of chromatin-associated hMSH5 under
various conditions. Results of these experiments indicated
that cisplatin treatment significantly enhanced the associa-
tion of hMSH5, but not hMSH5
Y742F, with chromatin (Fig-
ure 5A). Clearly, a fraction of chromatin-bound hMSH5
was tyrosine phosphorylated, and RNAi-mediated hMSH5
Figure 1 Cisplatin-mediated hMSH5 protein induction.( A) Time course of hMSH5 protein induction by cisplatin. 293, 293T, and A549 cells
were subjected to 20 μM cisplatin and hMSH5 levels were analyzed by Western blotting at the indicated time points. (B) Cisplatin dose-
dependent induction of hMSH5 protein in 293, 293T and A549 cells. Cells were treated with 2, 10 and 20 μM cisplatin for 24 hrs, and the levels
of hMSH5 were analyzed by Western blotting. (+) Lysates from 293T/f-hMSH5 cells were used as positive controls, and a-tubulin was used as a
loading control. (C) Cisplatin-induced hMSH5 induction occurred predominately in the nucleus. 293T and A549 cells were first treated with 10
μM cisplatin for 8 hrs, followed by Western blot analysis of hMSH5 levels in the nuclear and cytoplasmic fractions. RNAPII and a-tubulin were
used as nuclear and cytoplasmic markers, respectively.
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along with a corresponding reduction on the level of chro-
matin-associated hMSH5 (Figure 5A), suggesting hMSH5
tyrosine phosphorylation is required for cisplatin-induced
hMSH5 chromatin association. Since the hMSH5-hMSH4
heterocomplex has been suggested to play a role in the
process of HR [7], we also examined whether cisplatin
could trigger hMSH4 chromatin localization. The results
of a similar ChIP analysis performed with 293T/f45 cells
[31]–expressing both hMSH5 and hMSH4–indicated that
cisplatin could trigger hMSH4 localization to chromatin,
and this hMSH4-chromatin association was entirely
hMSH5-dependent as such RNAi-mediated hMSH5 silen-
cing could diminish hMSH4-chromatin association (Figure
5B). These observations suggest that c-Abl-mediated phos-
phorylation at hMSH5 Tyr
742 is important for cisplatin-
induced chromatin association of hMSH5 and hMSH4.
Because it is known that tyrosine phosphorylation dissoci-
ates hMSH5 from hMSH4 as well as c-Abl [10,14], it is
conceivable that chromatin-bound hMSH5 will have to be
in the dephosphorylated form before it can interact with
hMSH4. This view is consistent with the observed low
levels of tyrosine phosphorylation of chromatin-bound
hMSH5 (Figure 5A).
Figure 2 Cell cycle-dependent hMSH5 expression and cisplatin-triggered hMSH5 protein induction.( A) FACS analysis of cell cycle
synchronization. Data were analyzed by the use of FlowJo software (Dean-Jett model). Values are means ± standard deviation from 3
independent measurements. The expression of hMSH5 in 293T cells synchronized to G1, S, G2/M phases, and asynchronized controls were
examined by Western blot analysis. a-Tubulin immunoblot was used as a loading control. (B) Cisplatin-triggered hMSH5 induction in S phase
cells. 293T cells were synchronized at S phase and treated with 10 μM cisplatin for 8 hrs and followed by Western blot analysis of hMSH5
protein levels. a-Tubulin immunoblot was used as a loading control. (C) Treatment of S phase cells with cisplatin enhanced hMSH5 nuclear
accumulation. Cells synchronized at S phase were treated with 10 μM cisplatin for 8 hrs, and hMSH5 protein levels in the nuclear and
cytoplasmic fractions were evaluated by Western blotting. RNAPII and a-tubulin were used as nuclear and cytoplasmic loading controls,
respectively.
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lesions
The appearance of g-H2AX foci is an intrinsic biomar-
ker for the extent of DSB formation and can be used to
assess the combined effects of DNA damage and DNA
lesion repair [32]. It is known that the processing of cis-
platin-induced DNA lesions coincides with DSB forma-
tion [24]. Therefore, in order to analyze the effects of
hMSH5 on the processing of cisplatin-induced DSBs, g-
H2AX foci positive cells were quantified at 24 hrs post-
cisplatin treatment. Approximately 39.6% of 293T cells
and 35.5% of 293T/f-hMSH5 cells were g-H2AX foci
positive (Figure 5C and Additional file 1: Figure S2).
The small difference between these two cell lines indi-
cates that the effects of exogenously over-expressed
hMSH5 can be sufficiently masked by cisplatin-triggered
induction of endogenous hMSH5 (Figure 5C). However,
under identical experimental conditions, expression of
hMSH5
Y742F or silencing of hMSH5 significantly
increased the g-H2AX positive population to about
62.5% and 69.4%, respectively (Figure 5C), suggesting
that hMSH5 deficiency can significantly delay the reso-
lution of cisplatin-induced DSBs.
S i n c et h ek e yH Rp r o t e i nh R a d 5 1c o e x i s t sw i t h
hMSH5 and c-Abl in the same protein complex [10,11],
and Rad51 has been implicated in the repair of cispla-
tin-induced DSBs [33], we next investigated the possibi-
lity that hMSH5 functions together with hRad51 in the
processing of cisplatin-induced DNA lesions. The results
of immunostaining experiments demonstrated that, in
response to cisplatin, both hMSH5 and hRad51 formed
nuclear foci in both 293T and A549 cells (Additional
file 1: Figure S3). To determine whether the formation
of cisplatin-triggered hMSH5 foci was hRad51-depen-
dent, RNAi-mediated hMSH5 and hRad51 knockdown
were performed (Figure 5D). As shown in Figure 5E, the
formation of cisplatin-induced hMSH5 foci was signifi-
cantly diminished with the knockdown of either hMSH5
or hRad51 (left panel). However, the formation of cispla-
tin-induced hRad51 foci was not affected by the
Figure 3 Cisplatin triggered c-Abl-mediated hMSH5 tyrosine phosphorylation and hMSH5 nuclear foci formation.( A) Cisplatin treatment
led to hMSH5 tyrosine phosphorylation. 293T/f-hMSH5 cells were transiently transfected with myc-c-Abl and subjected to 20 μM cisplatin
treatment at 48 hrs post-transfection. Cell lysates were then prepared at indicated time points, and the status of tyrosine phosphorylation of
immunoaffinity-purified f-hMSH5 was analyzed by Western blotting. Untreated cells were used as controls. (B) Time course of cisplatin-induced
hMSH5 nuclear foci formation. 293T cells were treated with 10 μM of cisplatin for 2 hrs and hMSH5 foci were examined at 1, 6, and 24 hrs post-
treatment. Untreated cells were included as controls. Cells containing five or more hMSH5 nuclear foci were quantified. Error bars represent
standard deviations from the means of three independent measurements. Asterisks denote statistical significance (p < 0.05, Student t-test) In
order to assess the role of hMSH5 tyrosine phosphorylation in this process, we determined the tyrosine residue that can be phosphorylated by
c-Abl. To this end, Tyr-to-Phe mutations were introduced to the truncated c-Abl substrate hMSH5 cp-1 [10,29], and each of the resulting hMSH5
cp-1 mutants was co-expressed with c-Abl in BL21(DE3)-RIL cells and subsequently affinity-purified. Immunoblotting analysis of soluble fractions
of cell lysates and the affinity-purified hMSH5 cp-1 mutant proteins demonstrated that Tyr-to-Phe mutation at hMSH5 Tyr
742 resulted in a
complete abolishment of tyrosine phosphorylation, demonstrating that hMSH5 Tyr
742 is responsible for c-Abl-mediated phosphorylation (Figure
4A). It is of note that Tyr
742 is conserved between human and mouse, and it is located within the hMSH5 domain that interacts with hMSH4
[29,30]. Consistent with this, hMSH5 tyrosine phosphorylation is known to negatively regulate its interaction with hMSH4 [10].
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that hMSH5 acts downstream of hRad51 in recombina-
tional processing of cisplatin-induced DSBs.
hMSH5 deficiency renders cells more sensitive to cisplatin
toxicity
Cisplatin is known to induce G2/M arrest, and defec-
tive recombination often renders cells more sensitive
to its toxic effects. Therefore, we next analyzed the
effects of hMSH5 deficiency on cisplatin-triggered G2/
M arrest and survivability. Specifically, cell cycle analy-
sis was performed with cisplatin-treated 293T, 293T/f-
hMSH5, 293T/f-hMSH5
Y742F, and hMSH5-silenced
293T cells over a period of 72 hrs, in which the high-
est level of G2/M arrest occurred 24 hrs after cisplatin
treatment (Figure 6A). The baseline levels of G2/M
cells (i.e. at zero hr time point) for 293T, 293T/f-
hMSH5, and 293T/f-hMSH5
Y742F were identical (Fig-
ure 6A). However, there was a slight increase of the
basal G2/M population for hMSH5-silenced 293T cells,
presumably due to the effects of transient transfection
(Figure 6A). Although all cell lines displayed G2/M
arrest following cisplatin treatment, cells with
hMSH5
Y742F or hMSH5 RNAi had significantly larger
G2/M populations especially at late time points (Figure
6A). By 24 hrs, 293T/f-hMSH5
Y742F and hMSH5
knockdown cells, as compared to 293T cells, increased
G2/M arrest by 22.7% and 17.8%, respectively (Figure
6A). Moreover, cells with defective hMSH5 were
unable to resume normal cell cycle distribution at 72
hrs post-treatment, while 293T and 293T/f-hMSH5
cells were able to return to normal cell cycle distribu-
tion starting at 48 hrs (Figure 6A).
To validate whether cells harboring defective hMSH5
could confer a sensitive phenotype to cisplatin toxicity,
MTT assays and clonogenic survival analyses were per-
formed with 293T, 293T/f-hMSH5, and 293T/f-
hMSH5
Y742F cells treated with cisplatin. Evidently,
293T/f-hMSH5
Y742F cells were very sensitive to the
toxic effects of cisplatin in both the MTT and clono-
genic survival assays, whereas over-expression of
hMSH5 appeared to provide a moderate protection to
cisplatin toxicity (Figure 6B and 6C). Consistent with
the idea that hMSH5 functions together with hRad51 in
the process of HR, Rad51-deficient cells have also been
shown to exhibit a cisplatin-sensitive phenotype [33].
The dominant negative effects exerted by the phos-
phorylation-resistant mutant hMSH5
Y742F may be attrib-
uted to competition between hMSH5
Y742F and the
endogenous hMSH5 for binding to partner proteins
such as c-Abl, hRad51, hMRE11 and hMSH4. This view
is supported by the observed normal interaction of
hMSH5
Y742F with c-Abl or hMSH4 (Additional file 1:
Figure S4). Because c-Abl-mediated hMSH5 tyrosine
phosphorylation is known to reduce hMSH5 interaction
with c-Abl and hMSH4 [10], expression of hMSH5
Y742F
could also disrupt the dynamic composition of its asso-
ciated protein complex. Together, this study suggests a
Figure 4 Identification of hMSH5 tyrosine residues that could be phosphorylated by c-Abl.( A) Six hMSH5 cp-1 mutants, harboring various
Tyr-to-Phe mutations, were co-expressed with c-Abl in BL21 cells. The effects of these mutations on tyrosine phosphorylation were examined by
immunoblotting analysis of affinity-purified hMSH5 cp-1 proteins with an a-p-Tyr antibody. (B) Tyr
742 on hMSH5 was targeted by c-Abl kinase in
response to cisplatin treatment, and hMSH5 of hMSH5 from c-Abl. 293T/f-hMSH5 and 293T/f-hMSH5
Y742F cells were transfected with myc-c-Abl
and treated with 20 μM cisplatin 48 hrs post-transfection. Cell lysates were prepared 6 hrs after cisplatin treatment, and a-Flag
immunoprecipitates were analyzed by a-p-Tyr and a-c-Abl immunoblots. Four μM imatinib was used to inhibit c-Abl kinase activity.
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induced DSBs.
Discussion
Our current study has demonstrated an important role
for hMSH5 in the processing of cisplatin-elicited S
phase-dependent DSBs. Like other HR repair proteins,
hMSH5 is predominantly expressed during S and G2/M
phases of the cell cycle. Given the observation that silen-
cing of hRad51 can significantly compromise the forma-
tion of cisplatin-induced hMSH5 foci, it is conceivable
that hMSH5 acts downstream of hRad51 in the DSB
repair process. Disruption of hMSH5 function either by
RNAi or by the over-expression of a phosphorylation-
deficient mutant significantly increased the number of
cells displaying g-H2AX foci at 24 hrs after cisplatin
treatment, indicating an increase in the retention of cis-
platin-induced DSBs. In addition, disruption of hMSH5
enhances a sustained cisplatin-triggered G2 arrest,
thereby rendering cells more sensitive to cisplatin toxi-
city. It appears that the reduction of clonogenic surviva-
bility correlates well with the levels of g-H2AX foci in
293T, 293T/f-hMSH5, and 293T/f-hMSH5
Y742F cells at
24 hrs after cisplatin challenge. This observation is con-
sistent with previous reports showing that the level of g-
H2AX foci retention 24 hrs after treatment is a useful
indicator for cisplatin-mediated cell killing [28,34].
Although the precise role of hMSH5 in this process
remains to be delineated, the current evidence collec-
tively supports a scenario by which hMSH5 functions
Figure 5 Analysis of cisplatin-induced hMSH5 association with chromatin and nuclear foci formation.( A) 293T/f-hMSH5 and 293T/f-
hMSH5
Y742F cells were treated with 20 μM cisplatin, and cross-linked bulk chromatin was immunoprecipitated by an a-acetyl-histone H3
antibody 5 hrs post-treatment. The levels of chromatin-associated hMSH5 and its levels of phosphorylation were analyzed by Western blotting.
hMSH5 RNAi was used to knockdown hMSH5. Equal levels of acetyl-histone H3 and histone H4 were present in the immunoprecipitates. (B)
Analysis of hMSH4 chromatin association following cisplatin treatment. Chromatin was prepared from 293T/f45 cells treated with cisplatin. The
levels of chromatin-associated hMSH5 and hMSH4 were analyzed by Western blotting. hMSH5 RNAi was used to knockdown hMSH5. Mouse IgG
was used as a negative control. kDa, molecular weight (Mr) in thousands. (C) Examination of g-H2AX foci formation 24 hrs post cisplatin
exposure. 293T, 293T/f-hMSH5, 293T/f-hMSH5
Y742F, and 293T cells subjected to hMSH5 RNAi were used for this analysis. Cells possessing greater
than 15 foci/nucleus were graphically displayed. (D) Immunoblotting analysis of the effectiveness of hRad51 or hMSH5 knockdown in 293T cells
transfected with pmH1P-Bsd/hRad51 sh-1 or pmH1P-Bsd/hMSH5 sh-2. a-Tubulin was used as a loading control. kDa, molecular weight (Mr)i n
thousands. (E) Analysis of hMSH5 and hRad51 knockdown on cisplatin-induced hRad51 and hMSH5 nuclear foci formation. Cells were subjected
to 10 μM cisplatin for 2 hrs and were analyzed for hMSH5 foci formation 6 hrs post cisplatin removal. Cells that possessed five or more nuclear
foci for hMSH5 or hRad51 were scored. Error bars represent standard deviations of the means of three independent measurements. Statistically
significant differences between knockdown and control cells were indicated with asterisks (p < 0.05, Student t-test).
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platin-induced DSBs.
Due to its radio-sensitizing activity, cisplatin has been
frequently used in combination chemoradiation therapy
of human malignancies [35]. Presently, however, the
mechanisms underlying the effects of this radiosensitizer
are still being studied. It is suggested that cisplatin
adducts can block the repair of ionizing radiation-
induced DSBs by the nonhomologous end-joining path-
way [35,36]. However, the results of our current study
have raised another possibility that cisplatin-triggered
hMSH5 induction may potentially contribute to the
effectiveness of cisplatin combination chemoradiation
therapy. It is known that higher levels of hMSH5 pro-
mote IR-induced apoptosis [14]. Thus, in spite of the
fact that cisplatin-triggered hMSH5 induction can facili-
tate the repair of cisplatin-induced DSBs, the higher
levels of hMSH5 could promote a robust apoptotic
response to IR during cisplatin combination chemora-
diation therapy.
Figure 6 The effects of hMSH5 deficiency on cisplatin sensitivity.( A) hMSH5 deficiency increased G2/M arrest in response to cisplatin
treatment. 293T, 293T/f-hMSH5, 293T/f-hMSH5
Y742F, and 293T hMSH5 RNAi cells (hMSH5-silenced 293T cells) were treated with cisplatin for 2 hrs,
and were used for the cell cycle analysis at indicated time points. Percentages of G2/M cells were determined using FlowJo (Dean-Jett model).
(B) MTT assays were performed to determine the proliferation of 293T, 293T/f-hMSH5 and 293T/hMSH5
Y742F cells in response to cisplatin
treatment. (C) Clonogenic survival analysis of 293T, 293T/f-hMSH5, and 293T/f-hMSH5
Y742F cells treated with different doses of cisplatin. Cells
were treated with indicated doses for 1 hr and maintained in culture for 14 days to allow colony formation. Error bars represent standard
deviations from the means of three independent measurements. Asterisks denote p < 0.05 by Student t-test.
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involved in cisplatin-triggered DNA damage repair and
response. In fact, the roles of several other MMR family
members in mediating cellular responses to cisplatin-
induced DNA lesions have been studied [37-46]. As a
whole, these studies highlight two opposite effects of
individual MMR proteins on cellular responses to cispla-
tin toxicity. By functioning in the recognition and sig-
naling of cisplatin-induced DNA lesions, MMR proteins
can promote cell killing. On the other hand, they can
directly participate in the processing of cisplatin-induced
DSBs, thereby exerting a protective effect. It has been
shown that hMSH2 recognizes cisplatin-induced DNA
lesions through direct binding of DNA-cisplatin adducts
[41,42]. Cells defective in the expression of hMSH2 or
hMLH1 often exhibit a 2- to 4-fold increase in resis-
tance to cisplatin in comparison to corresponding con-
trols [37,39,40,44-46], indicating that hMSH2 and
hMLH1 are involved in mediating cisplatin-triggered
DNA damage signaling. Accordingly, cisplatin-resistant
cells derived from repetitive drug selection are fre-
quently associated with defective hMSH2 or hMLH1
expression [47-49]. However, the effects of hMSH2 or
hMLH1 in cellular sensitization to cisplatin have not
been observed in a few other studies, reflecting the com-
plex nature of cellular response to cisplatin-induced
DNA damage (reviewed in ref. [19]). It is conceivable
that the roles of hMSH2 and hMLH1 may be regulated
differently in the processes of repair and DNA damage
signaling in different cell types. In addition, difference in
cell cycle regulation may be another important factor in
controlling various levels of cellular sensitivity to cispla-
tin. In fact, it is demonstrated recently that disruption of
RPA’s role in cell cycle regulation synergistically
enhances the cytotoxic effects of cisplatin [50].
In contrast to aforementioned observations, a recent
study has revealed an important role for hMSH3 in the
repair of cisplatin-induced DSBs [38]. Using an isogenic
HCT116-derived cell line in which the expression of
hMSH3 can be controlled, Goel and colleagues [38]
demonstrated that hMSH3 deficiency sensitizes cells to
both cisplatin and oxaliplatin toxicity, and this effect of
hMSH3 is not dependent on the canonical MMR path-
way. In addition, in response to oxaliplatin treatment,
hMSH3-deficient cells sustain a higher level of g-H2AX,
suggesting that hMSH3 plays an important role in DSB
repair [38]. Intriguingly, the role of hMSH5 in mediating
cellular response to cisplatin-induced DSBs bears a
resemblance to that reported for hMSH3. In spite of
using different cell lines and different ways to disrupt
gene expression, cells deficient in hMSH5 or hMSH3
show comparable levels of reduction in clonogenic sur-
vivability in response to the same doses of cisplatin (Fig-
ure 6C) [38]. Although the timing for the elevation of
treatment-induced g-H2AX appears to be different in
cells subjected to RNAi-mediated silencing of hMSH5
or hMSH3 (Figure 5C) [38], these observations warrant
future studies to determine whether these two MutS
homologues act in the same repair process of cisplatin-
induced DSBs.
Intuitively, fertility preservation in male cancer
patients undergoing chemotherapy is highly desired, and
the relatively high levels of hMSH5 expression in the
testis would be expected to provide a protection against
cispaltin-induced DSBs. However, this effect of hMSH5
undoubtedly requires coordinated actions from a net-
work of proteins involved in the repair process, and the
efficiency of this pathway in various cell types in the tes-
tis is presently unknown. Since cisplatin represents a
main treatment choice for testicular cancers [15], it
would be interesting to investigate the relative expres-
sion levels of hMSH5 in testicular tumors and matched
normal testicular tissues. This information will be useful
for assessing the value of using hMSH5 as a prognosis
biomarker. Finally, our study has implicated that com-
bining hMSH5 disruption with cisplatin treatment
might be an alternative strategy for enhancing the thera-
peutic effects of cisplatin.
Conclusion
In summary, our study has demonstrated a role for
hMSH5 in protecting cells from cisplatin-induced DNA
damage. Inactivation of hMSH5 by RNAi or by expres-
sing a phosphorylation-deficient hMSH5 mutant elevates
cisplatin-induced G2 arrest and renders cells susceptible
to cisplatin toxicity.
Collectively, our data is compatible with the idea that
hMSH5 is involved in HR repair of cisplatin-induced
DSBs.
Methods
Cell lines and cell cultures
Stable cell line 293T/f-hMSH5
Y742F was generated by a
similar procedure that was previously described for
293T/f-hMSH5 [10]. All human cell lines were main-
tained in DMEM (Invitrogen, Carlsbad, CA) containing
10% FBS (Biomeda, Foster City, CA) and 1x Penicillin-
Streptomycin (Invitrogen). Cisplatin (Cis-diamminedi-
chloroplatinum (II) or CDDP) (Sigma, St. Louis, MO)
was used for the induction of DNA damage, and imati-
nib (Novartis, Basel, Switzerland) was used to inhibit c-
Abl kinase activity. Cell synchronization at different cell
cycle phases was performed by the use of standard
hydroxyurea (Sigma), double thymidine (Sigma), and
nocodazole (Sigma) based procedures [37,51]. Cell cycle
analysis was performed with the standard propidium
iodide (Invitrogen) staining procedure as described pre-
viously [52], in which at least 10,000 cells were analyzed
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Clonogenic survival and MTT analysis were performed
by the same procedures described previously [14,52].
Antibodies, Western blot analysis, and
immunoprecipitation (IP)
Antibodies used for performing IP and Western blot
analysis included a-FLAG M2 (Sigma, St. Louis, MO),
a-hMSH5 [29], a-hMSH4 [53], a-g-H2AX (Upstate
Laboratories, Inc., East Syracuse, NY), a-hRad51 (Cal-
biochem, Gibbstown, NJ), a-hMRE11 (Novus Biologicals
Inc., Littleton, CO), a-c-Abl (BD Pharmingen, San
Diego, CA), a-p-Tyr (Cell Signaling, Beverley, MA), a-
a-tubulin (Sigma, St. Louis, MO), a-acetyl histone H3
(Upstate), a-histone H4 (Cell Signaling), and a-RNAPII
(Upstate). IP and Western blotting were performed as
described previously [29].
Immunofluorescence analysis of nuclear foci
Analysis of hMSH5, hRad51, and g-H2AX foci forma-
tion was carried out by following a standard immuno-
fluorescence protocol. Primary and secondary antibodies
used for these experiments included a-hMSH5 [29], a-
hRad51 (Ab-1) pAb (Calbiochem), a-hRad51 (14B4)
m A b( N o v u sB i o l o g i c a l sI n c . ) ,a-g-H2AX (Upstate),
Oregon Green goat a-mouse IgG and Texas Red goat
a-rabbit IgG (Invitrogen, Carlsbad, CA). Cells were
mounted with Vectashield mounting media containing
DAPI (Vector Laboratories, Birminham, CA) and visua-
lized by a Zeiss Axioplan fluorescence microscope. For
nuclear foci quantification, cell counting was performed
at least three times with a total of > 200 cells counted.
Bacterial Protein expression and purification
Expression of various hMSH5 cp-1 Tyr-to-Phe mutants
and c-Abl in BL21(DE3)-RIL cells was performed using
the same experimental procedure as described pre-
viously [10]. PCR-based site-directed mutagenesis was
adapted to generate DNA sequences encoding hMSH5
Tyr-to-Phe mutations. Recombinant hMSH5 cp-1 or
hMSH5 cp-1 Tyr-to-Phe proteins were purified under
native conditions by the use of TALON Metal Affinity
Resins (Clontech, Mountainview, CA) as described pre-
viously [10].
Nuclear/cytoplasmic fractionation
Nuclear and cytoplasmic fractions were prepared by the
use of NE-PER Nuclear and Cytoplasmic Extraction
Reagents (Pierce, Thermo Fisher Scientific Inc., Rock-
ford, IL) in accordance with the manufacturer’sr e c o m -
mendation. Western blots with a-RNAPII (Upstate) and
a-a-tubulin (Sigma) antibodies were performed to vali-
date successful fractionation.
Chromatin association assays
Chromatin immunoprecipitation (ChIP) was performed
according to the manufacturer’s recommendation (EZ-
ChIP kit, Millipore, Billerica, MA). Antibodies used in
the experiments included a-acetyl histone H3 (Upstate),
mouse IgG (Upstate), a-p-Tyr (Cell Signaling), a-
hMSH5 [29], a-hMSH4 [53], and a-histone H4 (Cell
Signaling). To analyze chromatin-associated proteins,
bulk chromatin was immunoprecipitated with 10 μgo f
a-acetyl-histone H3. Immunoprecipitates were then sub-
jected to Western blotting analysis.
RNA interference
The generation of pmH1P-based RNAi constructs was
performed as previously described [54]. The efficiency of
RNAi-mediated gene silencing was validated by Western
blotting, and those displayed greater than 50% knock-
down were selected. The RNAi targets were hMSH5 sh-
2[ 1 4 ]a n dh R a d 5 1s h - 1( 5 ’-AAGGAGAGTGCGG
CGCTTC).
Additional material
Additional file 1: Figure S1 Representative images of CDDP-induced
hMSH5 foci formation at 1, 6, and 24 hrs post treatment. Cells were
treated with 10 μM CDDP for 2 hrs and hMSH5 foci formation was
analyzed at indicated time points after treatment. Figure S2.
Representative images of cisplatin-induced g-H2AX foci formation in
293T, 293T/f-hMSH5, 293T/f-hMSH5
Y742F, and 293T hMSH5 RNAi cells (48
hrs post transfection with pmH1P-Bsd/hMSH5 sh-2). (A) Untreated cells
were examined in parallel to establish the basal levels of g-H2AX signal
in these cell lines. (B) Cells were treated with 10 μM cisplatin for 2 hrs
followed by g-H2AX foci analysis at 24 hrs after cisplatin removal. Nuclei
are counterstained with DAPI and merged images are provided. Figure
S3. Representative images of CDDP-induced g-H2AX, hRad51, and hMSH5
foci formation in 293T and A549 cells. (A) Analysis of CDDP-triggered g-
H2AX and hMSH5 foci formation. (B) Analysis of CDDP-triggered g-H2AX
and hRad51 foci formation. (C) Analysis of CDDP-triggered hRad51 and
hMSH5 foci formation. Consistent with hMSH5 cytoplasmic and nuclear
distribution patterns, CDDP-induced hMSH5 foci appear to be present in
both cytoplasm and nucleus, whereas CDDP-induced g-H2AX and
hRad51 foci are predominately nuclear. Arrows indicate potential
overlaps of two different signals. Figure S4. Effects of hMSH5 Tyr
742-to-
Phe mutation on its interaction with hMSH4 and c-Abl. (A) Co-IP analysis
of the interaction between hMSH5 cp-1 Y742F and hMSH4. The results
indicated that hMSH5 cp-1 Y742F could interact with hMSH4 as efficient
as hMSH5 cp-1. (B) Co-IP analysis of the interaction between hMSH5
Y742F
and c-Abl. hMSH5
Y742F interacted with c-Abl in the same manner as
hMSH5 did.
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